Qiuji I. Wu - Publications

Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom.

Journal: BMJ open

Published: December 08, 2025

Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis.

Journal: Frontiers in public health

Published: October 18, 2025

Cost-effectiveness of tarlatamab versus chemotherapy for patients with small-cell lung cancer after platinum-based chemotherapy in the United States and China.

Journal: Frontiers in pharmacology

Published: October 07, 2025

A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 07, 2025

The causal effect of atopic dermatitis on lung cancer: A Mendelian randomization study.

Journal: Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)

Published: May 17, 2024

Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma.

Journal: Therapeutic advances in medical oncology

Published: January 06, 2024

Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy.

Journal: Frontiers in public health

Published: December 05, 2023

Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.

Journal: Cancer medicine

Published: November 15, 2023

Correction: Research trends of targeted therapy for cholangiocarcinoma from 2003 to 2022: a bibliometric and visual analysis.

Journal: Clinical and experimental medicine

Published: August 03, 2023

Research trends of targeted therapy for cholangiocarcinoma from 2003 to 2022: a bibliometric and visual analysis.

Journal: Clinical and experimental medicine

Published: May 12, 2023

The correlation of CD70 in immune characteristics and drug therapy of pan-cancer.

Journal: Human cell

Published: July 15, 2022

Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer.

Journal: BMC bioinformatics

Published: May 06, 2022